Denmark has become the world’s leading exporter of donor sperm, supplying clinics in more than one hundred countries and playing a central role in global fertility treatment.

The industry’s scale is such that one in every one hundred children born in Denmark today is conceived using donor sperm.

The sector’s success has been driven by high international demand, permissive regulation, advanced cryogenic technology, and the ability of Danish sperm banks to provide extensive donor profiles.

Prospective mothers can review detailed personal, physical, and background information about donors, a level of transparency that is rare in many other countries.

For some families, the appeal also lies in the possibility of having a blond, blue-eyed child, a preference that has become an unspoken commercial driver of the market.

That success, however, has exposed serious structural weaknesses.

A recent investigation revealed that the sperm of a single donor was used to conceive at least one hundred ninety-seven children across sixty-seven clinics in fourteen countries.

All of the children inherited a rare genetic mutation associated with aggressive cancer.

Several have died, and many others now require lifelong medical monitoring.

The donor began contributing sperm in two thousand five and continued for seventeen years.

During that time, his genetic material was repeatedly used across borders, often exceeding local limits on the number of families allowed to use a single donor.

In Belgium, for example, where the legal cap is fifteen families per donor, sperm from this individual was used by thirty-eight families, resulting in fifty-three children.

The case exposed how fragmented regulation enables excessive reuse of donor sperm without effective international oversight.

Neither recipient families nor donors themselves were fully informed about how frequently the same genetic material was being used.

As demand surged and supply remained constrained, clinics increasingly relied on a small pool of approved donors.

Only one to two percent of men who apply to donate sperm in Denmark pass the medical and genetic screening process.

This creates a bottleneck that encourages repeated use of the same donors, heightening the risk of genetic concentration, undisclosed sibling relationships, and undetected hereditary conditions.

The ethical implications extend beyond medical risk.

Children conceived from the same donor may live in the same city or region without knowing they are biologically related, raising the possibility of unknowingly forming intimate relationships or families.

These risks grow as donor sperm is exported globally without a unified tracking system.

The industry is now under pressure to reform.

Calls have intensified for an international donor registry to track cross-border sperm use and enforce limits on the number of families per donor.

Industry leaders warn that stricter regulation could reduce already limited supply and push desperate families toward unregulated markets.

Denmark’s fertility sector, valued at approximately one point three billion euros today and projected to grow sharply over the next decade, now faces a defining moment.

The tragedy has made clear that medical innovation without coordinated oversight carries human costs that cannot be ignored.